The US FDA has approved 6 NDAs and 1 BLAs in 2021, leading to treatments for patients and advances in the health care industryThe Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 68 novel products in 2021Additionally, last year in 2020, the US FDA…
Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for TrodelvyOur team at PharmaShots has compiled a list of top 20 oncology companies based on…
Immunology deals with the physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disordersWith the new advancement in the immune sector- global pharmaceuticals continue to grow in the field despite the disruption during COVID-19. As in 2019- Abbvie again secured…
In an interview with PharmaShots, Mike Crichton, Senior Vice President, Global Therapy Area Head, Specialty & Primary Care at GSK shares his views on the European Commission's approval of Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN).Shots:The European Commission approved the expanded use of GSK's…
In an interview with PharmaShots, Steve Bradford, Vice President, Medicines Commercialization Leader at GSK shed light on the US FDA's approval of Benlysta as the first and only approved treatment for both lupus and adult patients with active LN who are receiving standard therapy.Shots:The US FDA has approved GSK's Benlysta (belimumab) as the first and…
In a recent interview with PharmaShots, Dr. Riju Ray, MD, PhD, Senior Medical Lead at GSK, leading US medical affairs across asthma and COPD shared his views on how community-based pulmonologists are improving COPD management and education among referring PCPs.Shots:Pulmonologists identified 12 strong to moderate predictors of future COPD exacerbations, some of which were evaluated…
The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…
Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed- the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or…
To remain successful in the oncology market- change is now a key to adapt to this altering market dynamics. A recent development in science and technology platforms are likely to grow faster for cancer treatment in comparison to other therapy areas. However- despite robust levels of pipeline activity- oncology remains a challenging area for research…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop itThe outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019Â PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…

